PMV Pharmaceuticals (PMVP) awards 303,310 stock options to Chief Development Officer

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. reported that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options to purchase company stock and is classified as a grant or award acquisition. According to the terms, these options begin vesting on April 5, 2026, in 48 equal monthly installments, meaning the award vests gradually over four years, which is designed to align the executive’s incentives with the company’s longer-term performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jalota Deepika

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	303,310	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 303,310 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jalota Deepika

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.53	03/05/2026		A		303,310		(1)	03/05/2036	Common Stock	303,310	$0	303,310	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

	/s/ Robert Ticktin, by power of attorney	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PMV Pharmaceuticals (PMVP) disclose about Deepika Jalota in this Form 4?

PMV Pharmaceuticals disclosed that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options, classified as a grant or award acquisition, and is reported as direct ownership following the transaction.

How many stock options were granted to PMVP’s Chief Development Officer?

PMV Pharmaceuticals granted Chief Development Officer Deepika Jalota 303,310 employee stock options. These options give her the right to buy company shares in the future, subject to the vesting schedule described, which ties her potential ownership to continued service over several years.

What is the vesting schedule for Deepika Jalota’s PMVP stock options?

The stock options granted to Deepika Jalota vest in 48 equal monthly installments beginning on April 5, 2026. This four-year monthly vesting structure means she earns a portion of the options each month, encouraging long-term retention and alignment with shareholders.

What type of security was reported in PMVP’s Form 4 for Deepika Jalota?

The filing reports an Employee Stock Option (right to buy) as the security granted to Deepika Jalota. It is categorized as a derivative security, meaning it represents the right to acquire underlying PMV Pharmaceuticals common stock in the future, subject to vesting.

How is Deepika Jalota’s ownership recorded after this PMVP option grant?

After the grant, 303,310 stock options are reported as held by Deepika Jalota with direct ownership. The total represents the options subject to the new award, which will become exercisable over time according to the specified monthly vesting schedule starting April 5, 2026.

Does the PMVP Form 4 indicate this insider transaction was a purchase or a grant?

The transaction is identified as a grant, award, or other acquisition under code A, not an open-market purchase. It reflects employee stock options awarded to Chief Development Officer Deepika Jalota as part of compensation, rather than a cash stock purchase in the market.